Immunosuppressive treatment
ApprovedSmall molecule
SanofiImmunosuppressive treatment is one of 79 small molecule programs targeting Thrombotic Thrombocytopenic Purpura. It is currently in Approved.
3
Indications
3
Total Trials
1
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
131 competitors in Nephropathy
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisPhase 3
Zemplar
AbbViePhase 3
Simulect
NovartisPhase 3
Ultomiris
AstraZenecaPhase 3
Acetadote
AArbor Pharmaceuticals, Inc.
Phase 3
Tekturna
Tibotec Pharmaceuticals, IrelandPhase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Aurlumyn
BBTG International Inc.
Phase 3
Epoetin Beta
RochePhase 3
Povetacicept
Vertex PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nephropathy1 trial
Thrombotic Thrombocytopenic Purpura1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Immunosuppressive treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]